Orforglipron
ATTAIN-2
Eli Lilly · Phase 3 · Completed · Enrollment 1613
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo | Obesity + T2D | n/r | 72 | n/r | n/r |
| 6 mg Orforglipron QD | Obesity + T2D | 6 mg | 72 | n/r | n/r |
| 12 mg Orforglipron QD | Obesity + T2D | 12 mg | 72 | n/r | n/r |
| 36 mg Orforglipron QD | Obesity + T2D | 36 mg | 72 | n/r | n/r |